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Comprehensive Medication Management: Implications for the Patient and 
Pharmacist 
Abstract 
Since 1979, state pharmacy practice laws have begun to allow pharmacists to provide advanced levels of 
care in collaboration with prescribers. These might be termed medication therapy management, 
collaborative practice, comprehensive medication management and other variations. Invariably, 
pharmacists working closely with prescribers and patients in care of chronic disease have achieved 
dramatic results including improvement in surrogate markers, decreased rates of secondary large organ 
disease, decreased mortality, decreased hospitalizations, and as a result decreased spending.1-28 
This paper will discuss the profound impact of advanced practice models on patient care and the health 
care system, the current status of New York’s collaborative drug therapy management law, the 
comprehensive medication management proposal in Governor Cuomo’s fiscal year 2018 Budget bill, and 
its potential impact on morbidity and mortality when applied to chronic disease. 
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Since 1979, state pharmacy practice laws have begun to 
allow pharmacists to provide advanced levels of care in col-
laboration with prescribers. These might be termed medica-
tion therapy management, collaborative practice, compre-
hensive medication management and other variations. In-
variably, pharmacists working closely with prescribers and 
patients in care of chronic disease have achieved dramatic 
results including improvement in surrogate markers, de-
creased rates of secondary large organ disease, decreased 
mortality, decreased hospitalizations, and as a result de-
creased spending.1-28 
This paper will discuss the profound impact of advanced 
practice models on patient care and the health care system, 
the current status of New York’s collaborative drug therapy 
management law, the comprehensive medication manage-
ment proposal in Governor Cuomo’s fiscal year 2018 Budget 
bill, and its potential impact on morbidity and mortality 
when applied to chronic disease.  
The role of the pharmacist has continued to evolve in 
New York State over the past decade.  Mirroring other 
states, the pharmacy practice law has evolved to allow phar-
macists to collaborate with physician colleagues in collabo-
rative drug therapy management (“CDTM”).  This started in 
2011 with the creation of a “demonstration program” to as-
sess the ability of pharmacists in New York to improve out-
comes for patients in select settings (NYS Laws of 2011, ch. 
21; Education Law §§6801, 6801-a).  This pilot project was 
narrowly limited to pharmacists who had a doctor of phar-
macy degree or Master of Science in clinical pharmacy with 
at least one year of residency training and one additional 
year of practice or two years of residency training.  It also 
permitted pharmacists with the Bachelor of Science in phar-
macy degree and at least three years of experience, with at 
least one year of clinical work (all within the past seven 
years).  It was further limited to pharmacists in a “teaching 
hospital,” defined as a healthcare entity licensed under Arti-
cle 28 of the Public Health Law which receives funding for 
graduate medical education.  The demonstration program 
notably excluded nursing homes and community pharma-
cies. 
This pilot project, with data from participating pharma-
cists presented to the State Education Department, was an 
undisputed success. The report demonstrated the ability of 
the pharmacist to improve health outcomes and decrease 
morbidity and presumed mortality and health care costs in 
anticoagulation, diabetes, heart failure, human immunodefi-
ciency virus (HIV), oncology, and asthma.29 It also noted im-
proved patient and practitioner satisfaction.  This data led to 
the State Education Department recommend to the state 
legislature to continue this practice in New York State.  Phar-
macists in New York advocated for expansion of this to are-
as of practice where pharmacists can have an even bigger 
impact, including all healthcare settings, adding community 
pharmacies and nursing homes.   
 What ultimately passed only slightly modified the re-
quired qualifications in both credentials and practice site 
(New York State Laws of 2015, ch. 238). Currently, pharma-
cists in New York with a doctor of pharmacy can participate 
if: they have practiced for two or more years and 1 year of 
clinical experience providing clinical services within the past 
3 years (may include a residency) (NYS Education Law, sec-
tion 6801-a((2)(b)) AND they have board certification ac-
ceptable to the state Board of Pharmacy or completion of 
an accredited or accreditation-pending postgraduate phar-
macy residency program (8 NY Administrative Code, section 
63.10(c)(3)(iii)). If pharmacists possess a bachelor of science 
in pharmacy, the required years of experience increase to 3 
years, with at least one year providing direct patient clinical 
care in the past three years.  The pharmacist’s practice set-
ting was expanded to include any teaching or general hospi-
tal, including any diagnostic center, treatment center, or 
hospital-based outpatient department based on section 
2801 of the public health law.  It also allows for pharmacists 
to practice CDTM in a nursing home with an on-site phar-
macy. 
Note well that the law does not include the overwhelm-
ing majority of pharmacists in New York State practice, and 
are most accessible: the community pharmacy.  In the 2017-
2018 fiscal year, the Governor added into his initial draft 
budget a provision adding a new section 280-c to the Public 
Health Law entitled Comprehensive Medication Manage-
ment (“CMM”) that would allow pharmacists to participate in 
a more active way in patient care through a collaborative 
relationship with a patient’s primary care physician.  This was 
based on the knowledge that community pharmacists have 
a demonstrated skill set that, similar to their institutional 
colleagues, can decrease morbidity and mortality, and dra-
matically decrease costs.  The CMM proposal would enable 
qualified pharmacists, to engage in a voluntary collaborative 
agreement with a physician already providing care for a pa-
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tient who “has not met clinical goals of therapy, and is at risk 
for hospitalization”.  This created an entirely voluntary 
agreement where existing therapeutic relationships between 
physicians and community pharmacists were able to be cod-
ified to allow pharmacists to assist with the pharmacothera-
py management of patients through titration and modifica-
tion of medication regimens.  Additional requirements in-
cluded the need for the pharmacist to be able to document 
any changes in the medical record.  It is clear that only al-
lowed pharmacists who had a strong preexisting relation-
ship with a physician and proximity to his or her clinical site 
(based on need for EMR access) would be able to partici-
pate. Unfortunately, this provision was not ultimately enact-
ed into the final budget bill. 
It is tempting to think that only residency trained or clin-
ically experienced hospital-based pharmacists can have a 
significant impact on patient care.  However, there is ample 
published evidence that front-line community pharmacists 
can also have a positive impact on patient care.1-26  A prime 
example of this are the Asheville Project studies  conducted 
over the last 20 years. 3-6 These studies looked at the impact 
of using certificate trained community pharmacists to pro-
vide face-to-face medication therapy management on a 
regular basis for individuals with chronic diseases such as 
diabetes, hypertension, hyperlipidemia, and asthma.  In eve-
ry published study they found significant clinical improve-
ment. In addition, they observed decreased costs for the 
health care system attributed to the interventions by the 
pharmacist. These were, for the most part, not residency 
trained or hospital based pharmacists, just highly motivated 
community pharmacists who were willing to receive some 
additional training to be up to date on published guidelines 
for these chronic conditions. 
CMM will allow for pharmacists to participate in the care 
of patients that are high risk and living in underserved  areas 
where primary care is lacking.  Current CDTM regulations 
limit participating pharmacists to areas where there is al-
ready a high level of healthcare resources (cities, large 
health systems).  Indeed, as of May 2017, there are only 122 
pharmacists certified to engage in CDTM, with few applica-
tions pending. This is a highly talented pool of pharmacists, 
but the numbers are not on trajectory to serve the over-
whelming majority of New Yorkers. CMM, however, can in-
vite pharmacists in rural New York or in areas otherwise lim-
ited by current CDTM requirements to help participate in 
the care of patients.  Current law unjustly distributes the 
benefit of pharmacists to the lucky patients that go to 
healthcare facilities that are deemed appropriate.  However, 
the skillset of a pharmacist does not change just because he 
or she is practicing in a different facility (e.g. community 
pharmacy). Implementation of CMM would afford all New 
Yorkers full access to the clinical skill set of a pharmacist 
practicing at the top of his or her license in arguably the 
most accessible healthcare location: the community phar-
macy. 
Enabling qualified pharmacists to provide CMM in all 
practice areas is also an issue of public protection. Compre-
hensive medication management, CDTM, or whatever else 
we might choose to call it, is proven to decrease morbidity 
and mortality in the context of chronic disease. If we are a 
patient-centered profession, we have an ethical imperative 
to advocate for  pharmacists to provide this level of care.  
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